Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals

AUPH | NASDAQ
Chart Builder DCF Calculator
$15.48
-$0.25 (-1.59%)
At close: Nov 16, 2026, 4:00 PM ET
$15.81
+$0.33 (+2.13%)
After-hours: Nov 16, 2026, 7:40 PM ET
-1.59%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
83.1
+1.0 pts
Fundamentals Excellent
Market Sentiment Neutral
Moat Narrow
Sector Rank #11/1021 (Top 1%)

Key Statistics

Market Data

Market Cap $2.07B
1D Range
15.30 15.81
52W Range
13.95 18.62

Valuation (TTM)

PE 6.76
PB 3.15
EV/EBITDA 8.41

Valuation (NTM)

Forward PE 16.22
Forward PEG 0.28
Price Target $17.00
Loading financial charts...

Profile

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a v...

Sector Healthcare
Industry Biotechnology
Employees 128
IPO Date Sep 3, 2014
Fiscal Year January - December

Latest News

Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates

18 days ago · zacks.com

Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

18 days ago · businesswire.com

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline

21 days ago · zacks.com

Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term

22 days ago · zacks.com

Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term

25 days ago · zacks.com

Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

3 months ago · zacks.com

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

3 months ago · benzinga.com

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Settles Patent Litigation with Teva

3 months ago · businesswire.com

Aurinia Settles Patent Litigation with Teva
Aurinia Pharmaceuticals Doubles Down On Its Pipeline

3 months ago · seekingalpha.com

Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

3 months ago · zacks.com

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Earnings

Latest Earnings
Oct 30, 2026
EPS
$0.23
Beat +4.55%
REV
$83.7M
Beat +0.11%
Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Hold
Price Target
$17.00
Upside
+9.82%
Buy (1)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.